Evolution of care for patients with relapsed glioblastoma.

about

Recurrent Glioblastoma: Where we stand Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma.Standards of care for treatment of recurrent glioblastoma--are we there yet?

P2860

Q26765042-69185ACA-9238-4385-B2F9-4513A18D9D36 Q35676452-7D6A7AC1-907B-4A5A-81FE-3A1C6185F907 Q36500401-D4C8570D-6855-4613-9BFC-AFE543FB663E

P2860

Evolution of care for patients with relapsed glioblastoma.

Item

http://www.wikidata.org/entity/Q37952240

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Evolution of care for patients with relapsed glioblastoma.

@en

Evolution of care for patients with relapsed glioblastoma.

@nl

type

Item

label

Evolution of care for patients with relapsed glioblastoma.

@en

Evolution of care for patients with relapsed glioblastoma.

@nl

prefLabel

Evolution of care for patients with relapsed glioblastoma.

@en

Evolution of care for patients with relapsed glioblastoma.

@nl

P1476

Evolution of care for patients with relapsed glioblastoma

@en

P2093

Pilar Teixidor

http://www.w3.org/2001/XMLSchema#string

Salvador Villá

http://www.w3.org/2001/XMLSchema#string

P2860

Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.

Radiotherapeutic alternatives for previously irradiated recurrent gliomas.

P304

1719-1729

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERA.11.152

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Carmen Balaña

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22050021

http://www.w3.org/2001/XMLSchema#string

Evolution of care for patients with relapsed glioblastoma.

about

P2860

P2860

Evolution of care for patients with relapsed glioblastoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698